Literature DB >> 10394136

Three-dimensional spheroid model in tumor biology.

M T Santini1, G Rainaldi.   

Abstract

It is becoming more and more apparent that monolayer cultures of tumor cells cannot completely represent the characteristics of three-dimensional solid tumors. Consequently, the multicellular tumor spheroid model, which is of intermediate complexity between in vivo tumors and monolayer cultures, was developed. In this review, the major similarities between spheroids and solid tumors are discussed. After a brief survey of the different spheroid culturing techniques, the general morphological and growth characteristics of these systems are examined and compared to solid tumors. Finally, selected studies regarding the use of tumor spheroids to examine cell response to antineoplastic agents and radiation, cell death including both necrosis and apoptosis and cell adhesion in spheroids are reviewed.

Entities:  

Mesh:

Year:  1999        PMID: 10394136     DOI: 10.1159/000028065

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  76 in total

1.  Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines.

Authors:  Anjali Shiras; Arti Bhosale; Anjali Patekar; Varsha Shepal; Padma Shastry
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Generation and differentiation of microtissues from multipotent precursor cells for use in tissue engineering.

Authors:  Fabian Langenbach; Karin Berr; Christian Naujoks; Andrea Hassel; Michael Hentschel; Rita Depprich; Norbert R Kubler; Ulrich Meyer; Hans-Peter Wiesmann; Gesine Kögler; Jörg Handschel
Journal:  Nat Protoc       Date:  2011-10-13       Impact factor: 13.491

Review 3.  Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment.

Authors:  Hsieh-Fu Tsai; Alen Trubelja; Amy Q Shen; Gang Bao
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

4.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

5.  The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Authors:  Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

6.  Spheroid-based drug screen: considerations and practical approach.

Authors:  Juergen Friedrich; Claudia Seidel; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

7.  Spatially adaptive active contours: a semi-automatic tumor segmentation framework.

Authors:  Cristina Farmaki; Konstantinos Marias; Vangelis Sakkalis; Norbert Graf
Journal:  Int J Comput Assist Radiol Surg       Date:  2010-05-17       Impact factor: 2.924

8.  Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition.

Authors:  Khatri Latha; Weiguo Zhang; Nathalie Cella; Heidi Y Shi; Ming Zhang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 9.  [Relevance of cell culture models in cutaneous tumour biology: part II: complex culture systems].

Authors:  J Hatina; T Ruzicka
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

10.  In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.

Authors:  Louis-Bastien Weiswald; Jean-Marc Guinebretière; Sophie Richon; Dominique Bellet; Bruno Saubaméa; Virginie Dangles-Marie
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.